📰 Nasdaq Itrm News
Nasdaq Itrm News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Nasdaq Itrm. Real-time updates on events, politics, business and more.
May 2, 2024
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report)‘s stock had its “buy” rating restated by equities researchers at HC Wainwright in a research report issued on Tuesday, Benzinga reports. They presently have a $6.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 277.36% from the stock’s current price. Iterum […]
April 22, 2024
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) and RedHill Biopharma (NASDAQ:RDHL – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, dividends, risk, valuation, profitability and analyst recommendations. Analyst Ratings This is a breakdown of […]
February 8, 2024
Iterum Therapeutics plc (NASDAQ:ITRM – Free Report) – HC Wainwright issued their FY2028 EPS estimates for shares of Iterum Therapeutics in a note issued to investors on Wednesday, February 7th. HC Wainwright analyst E. Arce expects that the company will earn $0.16 per share for the year. HC Wainwright currently has a “Buy” rating and […]
December 30, 2023
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 25,000 shares of the business’s stock in a transaction dated Friday, December 22nd. The shares were purchased at an average price of $1.40 per share, for a total transaction of $35,000.00. Following the acquisition, the director now owns 113,754 shares of the […]
November 28, 2023
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 20,000 shares of Iterum Therapeutics stock in a transaction on Wednesday, November 22nd. The shares were acquired at an average cost of $2.03 per share, with a total value of $40,600.00. Following the completion of the transaction, the director now directly owns […]
November 28, 2023
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne acquired 20,000 shares of the company’s stock in a transaction dated Wednesday, November 22nd. The shares were bought at an average cost of $2.03 per share, with a total value of $40,600.00. Following the completion of the acquisition, the director now directly owns […]
November 28, 2023
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) Director Michael W. Dunne purchased 20,000 shares of the stock in a transaction on Wednesday, November 22nd. The stock was acquired at an average price of $2.03 per share, for a total transaction of $40,600.00. Following the completion of the purchase, the director now directly owns 78,754 […]
September 19, 2023
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) shares dropped 3.4% during mid-day trading on Monday . The stock traded as low as $0.75 and last traded at $0.75. Approximately 17,282 shares were traded during trading, a decline of 71% from the average daily volume of 60,503 shares. The stock had previously closed at $0.78. […]
August 27, 2023
Iterum Therapeutics plc (NASDAQ:ITRM – Get Free Report) was the recipient of a large growth in short interest during the month of August. As of August 15th, there was short interest totalling 85,700 shares, a growth of 72.8% from the July 31st total of 49,600 shares. Currently, 0.7% of the company’s shares are short sold. […]
August 7, 2023
Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Friday, August 11th. Analysts expect the company to announce earnings of ($0.80) per share for the quarter. Iterum Therapeutics (NASDAQ:ITRM – Get Free Report) last released its quarterly earnings data on Friday, May 12th. The […]